Drug Shortage Report for TEVETEN PLUS
Report ID | 169169 |
Drug Identification Number | 02253631 |
Brand name | TEVETEN PLUS |
Common or Proper name | HYDROCHLOROTHIAZIDE EPROSARTAN |
Company Name | BGP PHARMA ULC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | HYDROCHLOROTHIAZIDE EPROSARTAN |
Strength(s) | 12.5MG 600MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 2x14 |
ATC code | C09DA |
ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2021-12-06 |
Estimated end date | |
Actual end date | 2023-08-30 |
Shortage status | Resolved |
Updated date | 2024-12-10 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2024-12-10 | French | Compare |
v3 | 2024-12-10 | English | Compare |
v2 | 2022-09-13 | French | Compare |
v1 | 2022-09-13 | English | Compare |
Showing 1 to 4 of 4